Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 13
- Registration Number
- NCT05225805
- Locations
- ๐บ๐ธ
University of Kansas School of Medicine, Kansas City, Kansas, United States
๐บ๐ธBoston Children's Hospital, Boston, Massachusetts, United States
๐บ๐ธNew York Medical College, Valhalla, New York, United States
4-way Crossover QT Evaluation in Healthy Subjects
- Conditions
- Cardiac Repolarization in Healthy Subjects
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 41
- Registration Number
- NCT03709927
- Locations
- ๐บ๐ธ
Pharmaron, Baltimore, Maryland, United States
PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)
- Conditions
- Pediatric ALL
- Interventions
- Drug: ZTI-01 100 mg/kgDrug: ZTI-01 75 mg/kg
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 21
- Registration Number
- NCT03709914
- Locations
- ๐บ๐ธ
Children's Hospital of Orange County, Orange, California, United States
๐บ๐ธRady Children's Hospital, San Diego, California, United States
๐บ๐ธKosair Charities Pediatric Clinical Research Unit, Louisville, Kentucky, United States
A Study to Assess Mass Balance Recovery, Metabolite Profile and Identification of IV and Oral 14C-BC-3781
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 10
- Registration Number
- NCT03131141
- Locations
- ๐ฌ๐ง
Quotient Clinical, Nottingham, United Kingdom
Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
- Conditions
- Community Acquired Pneumonia
- Interventions
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 738
- Registration Number
- NCT02813694
- Locations
- ๐บ๐ธ
1080, Beverly Hills, California, United States
๐บ๐ธSite 1065, Fresno, California, United States
๐บ๐ธ1078, Northridge, California, United States
Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections
- Conditions
- Urinary Tract Infection SymptomaticUrinary Tract Infection ComplicatedAcute Pyelonephritis
- Interventions
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 465
- Registration Number
- NCT02753946
Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia
- Conditions
- Community Acquired Pneumonia
- Interventions
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 551
- Registration Number
- NCT02559310
- Locations
- ๐บ๐ธ
Site 1006, Hazard, Kentucky, United States
๐บ๐ธSite 1008, Shreveport, Louisiana, United States
๐บ๐ธSite 1005, Minneapolis, Minnesota, United States
Bioavailability and Pharmacokinetics of Lefamulin When Administered to Fed and Fasted Healthy Subjects
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 20
- Registration Number
- NCT02557789
- Locations
- ๐ฌ๐ง
Quotient Clinical, Nottingham, United Kingdom
Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 210
- Registration Number
- NCT01119105
- Locations
- ๐บ๐ธ
BC-3781 Study Center 002, Chula Vista, California, United States
๐บ๐ธBC-3781 Study Center 001, La Mesa, California, United States
๐บ๐ธBC-3781 Study Center 003, Oceanside, California, United States